TNG:EPA
Transgene SA
0,68 €
arrow_downward
−0,73%(−0,0050) 1 p
19. okt, 17:35:04 GMT +2 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse TNG põhistatistika genereerimine…
Ava
0,69 €
Kõrge
0,70 €
Madal
0,68 €
Turu kapit.
191,94 mln
Keskm. maht
111,65 tuh
Maht
53,57 tuh
52 näd kõrgeim
1,50 €
52 näd madalaim
0,68 €
Aktsiatulu
−0,17 €
Käibivad aktsiad
278,56 mln
Töötajate arv
152
Ava
0,69 €
Kõrge
0,70 €
Madal
0,68 €
Turu kapit.
191,94 mln
Keskm. maht
111,65 tuh
Maht
53,57 tuh
52 näd kõrgeim
1,50 €
52 näd madalaim
0,68 €
Aktsiatulu
−0,17 €
Käibivad aktsiad
278,56 mln
Töötajate arv
152
Uudised
Veebiallikatest ja uudistepartneritelt
Kalkine Media
·
20 minuti eest
Can Medical Strength Meet Reform Talk at Aurora Cannabis (NASDAQ:ACB)?
The Guardian
·
34 minuti eest
Is this the beginning of the end of the AI stock market boom?
upi
·
12 tunni eest
New York Stock Exchange extends trading hours
Profiil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Teave üksuse Transgene SA kohta